Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 214 of the 223 references it cites were found in a registry or an index, and 9 are not checked yet.

Ribosome Biogenesis and Translational Control in Skeletal Muscle Atrophy and Hypertrophy: Mechanisms and Therapeutic Perspectives

Open access
Xu, Miaomiao, Liu, Xiaoguang · 2026 · Biomolecules

Abstract

Maintenance of skeletal muscle mass is essential for mobility, metabolic homeostasis, and clinical outcomes across a wide spectrum of physiological and pathological conditions. While muscle atrophy and hypertrophy have traditionally been interpreted through upstream anabolic–catabolic signaling and proteolytic pathways, accumulating evidence indicates that ribosome biogenesis and translational control represent rate-limiting determinants of muscle plasticity. However, this regulatory layer remains insufficiently integrated into current models of muscle adaptation and disease. In this review, we synthesize recent advances in ribosomal RNA transcription, ribosomal protein dynamics, and translational regulation in skeletal muscle, with particular emphasis on signaling networks governed by mTORC1, c-Myc, AMPK, and FOXO. We highlight ribosome biogenesis as a central hub linking mechanical loading, nutrient availability, inflammatory stress, and metabolic status to protein synthesis capacity. Evidence from human and animal studies demonstrates that impaired ribosome production and translational efficiency precede and predict muscle atrophy in disuse, aging, cancer cachexia, and chronic disease, whereas ribosome expansion is a prerequisite for sustained hypertrophy. Beyond quantitative regulation, we discuss the emerging concept of ribosome heterogeneity as a qualitative layer of translational control that may enable selective mRNA translation during muscle growth, stress adaptation, and degeneration. We further examine ribosome–mitochondria crosstalk as a critical but underexplored mechanism coordinating anabolic capacity with cellular energetics. Finally, we outline therapeutic implications, highlighting exercise, nutritional strategies, and indirect pharmacological interventions that preserve ribosomal competence, and propose ribosome-based biomarkers as promising tools for precision management of muscle-wasting disorders. Collectively, this review positions ribosome biology as a translationally relevant framework bridging molecular mechanisms with therapeutic perspectives in skeletal muscle atrophy and hypertrophy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom16030406

Cites

214 of 223 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Literature selection flow diagram.
Figure 1 Literature selection flow diagram.CC BY · PubMed Central
Figure 2 Overview of ribosome biogenesis in skeletal muscle. This schematic illustrates the sequential process of ribosome biogenesis in skeletal muscle cells. In the nucleolus, rDNA is transcribed by Pol I to produce 47S pre-rRNA, which is processed into 18S, 5.8S, and 28S rRNAs and modified by RPs under the guidance of snoRNAs. Meanwhile, Pol III transcribes 5S DNA to generate 5S rRNA. The 18S rRNA associates with RPs to form the 40S subunit, whereas 5S, 5.8S, and 28S rRNAs combine with RPs to form the 60S subunit. Both subunits are exported to the cytoplasm, where they assemble into functional ribosomes that drive protein synthesis and support muscle adaptation. Note: Pol I, RNA polymerase I; Pol III, RNA polymerase III; rDNA, ribosomal DNA; rRNA, ribosomal RNA; RP, ribosomal protein; snoRNA, small nucleolar RNA. Blue arrows indicate RP import; red arrows indicate nuclear export; purple arrows indicate snoRNA-guided modifications essential for ribosome stability and function; gray arrows indicate the direction of molecular assembly and protein synthesis.
Figure 2 Overview of ribosome biogenesis in skeletal muscle. This schematic illustrates the sequential process of ribosome biogenesis in skeletal muscle cells. In the nucleolus, rDNA is transcribed by Pol I to produce 47S pre-rRNA, which is processed into 18S, 5.8S, and 28S rRNAs and modified by RPs under the guidance of snoRNAs. Meanwhile, Pol III transcribes 5S DNA to generate 5S rRNA. The 18S rRNA associates with RPs to form the 40S subunit, whereas 5S, 5.8S, and 28S rRNAs combine with RPs to form the 60S subunit. Both subunits are exported to the cytoplasm, where they assemble into functional ribosomes that drive protein synthesis and support muscle adaptation. Note: Pol I, RNA polymerase I; Pol III, RNA polymerase III; rDNA, ribosomal DNA; rRNA, ribosomal RNA; RP, ribosomal protein; snoRNA, small nucleolar RNA. Blue arrows indicate RP import; red arrows indicate nuclear export; purple arrows indicate snoRNA-guided modifications essential for ribosome stability and function; gray arrows indicate the direction of molecular assembly and protein synthesis.CC BY · PubMed Central
Figure 3 Signaling network regulating ribosome biogenesis and translational control in skeletal muscle. This diagram illustrates the intricate interplay of anabolic and catabolic signaling pathways governing ribosome biogenesis and translational control in skeletal muscle. Anabolic stimuli (e.g., exercise, nutrition) activate mTORC1 and c-Myc (green arrows), promoting rRNA transcription (via Pol I, TIF-1A, UBF) and RP translation (via S6K1, 4EBP) to enhance ribosome biogenesis and translational capacity, leading to muscle hypertrophy. Conversely, catabolic stress (e.g., inflammation, energy depletion) activates AMPK, FOXO, and inflammatory signals (e.g., IL-6/STAT3) (red arrows), which suppress RNA Pol I activity, downregulate ribosomal genes, and compromise nucleolar integrity, thereby diminishing translational efficiency and contributing to muscle atrophy. The balance between these opposing forces precisely orchestrates ribosome function, dictating the anabolic or catabolic fate of muscle. Note: AMPK, AMP-activated protein kinase; c-Myc, cellular myelocytomatosis oncogene; 4EBP, eukaryotic translation initiation factor 4E-binding protein; FOXO, Forkhead box protein O; IL-6, interleukin-6; mTORC1, mechanistic target of rapamycin complex 1; Pol I, RNA polymerase I; rRNA, ribosomal RNA; RP, ribosomal protein; S6K1, ribosomal protein S6 kinase 1; STAT3, signal transducer and activator of transcription 3; TIF-1A, transcription initiation factor 1A; UBF, upstream binding factor. Green arrows and lines indicate activating or promoting effects. Red arrows denote the progression of signaling within the catabolic pathway. T-bar symbols (⊥) indicate inhibitory effects (e.g., AMPK-mediated inhibition of the mTORC1 pathway and FOXO-mediated suppression of ribosome biogenesis).
Figure 3 Signaling network regulating ribosome biogenesis and translational control in skeletal muscle. This diagram illustrates the intricate interplay of anabolic and catabolic signaling pathways governing ribosome biogenesis and translational control in skeletal muscle. Anabolic stimuli (e.g., exercise, nutrition) activate mTORC1 and c-Myc (green arrows), promoting rRNA transcription (via Pol I, TIF-1A, UBF) and RP translation (via S6K1, 4EBP) to enhance ribosome biogenesis and translational capacity, leading to muscle hypertrophy. Conversely, catabolic stress (e.g., inflammation, energy depletion) activates AMPK, FOXO, and inflammatory signals (e.g., IL-6/STAT3) (red arrows), which suppress RNA Pol I activity, downregulate ribosomal genes, and compromise nucleolar integrity, thereby diminishing translational efficiency and contributing to muscle atrophy. The balance between these opposing forces precisely orchestrates ribosome function, dictating the anabolic or catabolic fate of muscle. Note: AMPK, AMP-activated protein kinase; c-Myc, cellular myelocytomatosis oncogene; 4EBP, eukaryotic translation initiation factor 4E-binding protein; FOXO, Forkhead box protein O; IL-6, interleukin-6; mTORC1, mechanistic target of rapamycin complex 1; Pol I, RNA polymerase I; rRNA, ribosomal RNA; RP, ribosomal protein; S6K1, ribosomal protein S6 kinase 1; STAT3, signal transducer and activator of transcription 3; TIF-1A, transcription initiation factor 1A; UBF, upstream binding factor. Green arrows and lines indicate activating or promoting effects. Red arrows denote the progression of signaling within the catabolic pathway. T-bar symbols (⊥) indicate inhibitory effects (e.g., AMPK-mediated inhibition of the mTORC1 pathway and FOXO-mediated suppression of ribosome biogenesis).CC BY · PubMed Central
Figure 4 Structural basis of ribosome specialization in skeletal muscle. This figure illustrates how ribosomal protein composition directs selective translation and influences muscle adaptation. (Left) During muscle hypertrophy, ribosomes containing specific RPs (RPL3 and RPS6) are upregulated, selectively translating mRNAs critical for growth. (Right) In contrast, deletion or mutation of RPL3L disrupts ribosomal function, alters translational dynamics, and reduces expression of contractile proteins, leading to impaired muscle development. Note: RPs, ribosomal proteins; RPL3, Ribosomal Protein L3; RPS6, Ribosomal Protein S6; RPL3L, Ribosomal Protein L3-like; Δ, deletion or mutation.
Figure 4 Structural basis of ribosome specialization in skeletal muscle. This figure illustrates how ribosomal protein composition directs selective translation and influences muscle adaptation. (Left) During muscle hypertrophy, ribosomes containing specific RPs (RPL3 and RPS6) are upregulated, selectively translating mRNAs critical for growth. (Right) In contrast, deletion or mutation of RPL3L disrupts ribosomal function, alters translational dynamics, and reduces expression of contractile proteins, leading to impaired muscle development. Note: RPs, ribosomal proteins; RPL3, Ribosomal Protein L3; RPS6, Ribosomal Protein S6; RPL3L, Ribosomal Protein L3-like; Δ, deletion or mutation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 215 references

Cited by

See all 8

Metadata

Authors
Xu, M., & Liu, X.
Affiliations
  • Guangdong University of Education (CN)
  • Guangzhou Sport University (CN)
Corresponding author
Liu, Xiaoguang
Venue
Biomolecules
Publisher
MDPI AG
Published
2026-03-10
Volume
16
Issue
3
Pages
406
ISSN
2218-273X (ISSN-L)
OpenAlex
W7134835948
Cited by
6
References
215
Citations by year
2026: 6
FWCI
4.02
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (32300964)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
Keywords
ribosome biogenesis, translational regulation, skeletal muscle atrophy, skeletal muscle hypertrophy, rDNA transcription, mTORC1 signaling, c-Myc, AMPK, FOXO, ribosome heterogeneity, disuse atrophy, cancer cachexia, aging, exercise therapy, dietary intervention, muscle atrophy
MeSH terms
Animals, Organelle Biogenesis, Humans, Hypertrophy, Muscular Atrophy, Ribosomal Proteins, Ribosomes, Protein Biosynthesis, Signal Transduction, Muscle, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ribosome Biogenesis and Translational Control in Skeletal Muscle Atrophy and Hypertrophy: Mechanisms and Therapeutic Perspectives. https://app.cochat.ai/papers/10.3390/biom16030406
The paper
Xu, M., & Liu, X. (2026). Ribosome Biogenesis and Translational Control in Skeletal Muscle Atrophy and Hypertrophy: Mechanisms and Therapeutic Perspectives. Biomolecules. https://doi.org/10.3390/biom16030406

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.